Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0261
-0.0039 (-13.00%)
Jul 31, 2026, 11:52 AM EST
Adaptimmune Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 25.95 | 91.14 | 143.99 | 108.03 | 149.95 |
Short-Term Investments | - | 60.47 | 2.95 | 96.57 | 219.63 |
Cash & Short-Term Investments | 25.95 | 151.61 | 146.94 | 204.61 | 369.58 |
Cash Growth | -82.88% | 3.18% | -28.18% | -44.64% | 0.37% |
Accounts Receivable | 6.99 | 1.45 | 0.82 | 7.44 | 0.75 |
Other Receivables | 3.48 | 12.93 | 46.1 | 30.16 | 30.77 |
Total Trade Receivables | 10.47 | 14.38 | 46.92 | 37.6 | 31.53 |
Inventory | - | 7.32 | - | - | - |
Other Current Assets | 8.89 | 13.73 | 14.1 | 14.01 | 17.13 |
Total Current Assets | 45.31 | 187.04 | 207.96 | 256.22 | 418.23 |
Net Property, Plant & Equipment | 16.29 | 48.79 | 69.59 | 69.96 | 51.35 |
Other Intangible Assets | 0.02 | 8.52 | 5.65 | 5.7 | 13.42 |
Other Long-Term Assets | 1.73 | 2.07 | 3.03 | 3.07 | 2.22 |
Total Assets | 63.36 | 246.42 | 286.22 | 334.95 | 485.22 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 16.61 | 40.98 | 38.43 | 35.97 | 38.02 |
Current Portion of Leases | 4.93 | 4.72 | 5.39 | 2.8 | 2.64 |
Unearned Revenue | - | 12.3 | 28.97 | 23.52 | 22.2 |
Other Current Liabilities | 0.7 | 6.85 | - | 3.23 | - |
Total Current Liabilities | 22.24 | 64.85 | 72.8 | 65.52 | 62.86 |
Long-Term Debt | - | 50.24 | - | - | - |
Long-Term Leases | 9.15 | 19.33 | 19.93 | 20.57 | 24.42 |
Other Long-Term Liabilities | - | 98.96 | 150.46 | 162.19 | 177.9 |
Total Long-Term Liabilities | 9.15 | 168.53 | 170.4 | 182.76 | 202.32 |
Total Liabilities | 31.39 | 233.38 | 243.2 | 248.28 | 265.18 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2.16 | 2.09 | 1.87 | 1.4 | 1.34 |
Additional Paid-in Capital | 961 | 959.23 | 930.2 | 869.03 | 856.22 |
Accumulated Other Comprehensive Income | -16.74 | -9.78 | -11.5 | -8.99 | -18.06 |
Retained Earnings | -914.45 | -938.5 | -877.55 | -774.77 | -619.46 |
Shareholders' Equity | 31.97 | 13.04 | 43.03 | 86.67 | 220.05 |
Total Liabilities & Equity | 63.36 | 246.42 | 286.22 | 334.95 | 485.22 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 14.08 | 74.29 | 25.33 | 23.37 | 27.06 |
Net Cash (Debt) | 11.87 | 77.32 | 121.61 | 181.23 | 342.52 |
Net Cash Growth | -84.65% | -36.42% | -32.90% | -47.09% | -0.58% |
Net Cash Per Share | 0.01 | 0.04 | 0.10 | 0.19 | 0.37 |
Book Value | 31.97 | 13.04 | 43.03 | 86.67 | 220.05 |
Book Value Per Share | 0.02 | 0.01 | 0.04 | 0.09 | 0.24 |
Tangible Book Value | 31.95 | 4.52 | 37.38 | 80.97 | 206.62 |
Tangible Book Value Per Share | 0.02 | 0.00 | 0.03 | 0.08 | 0.22 |